MYELODYSPLASTIC SYNDROME(MDS)
&
MYELOPROLIFERATIVE DISORDERS
Dr ANIL KUMAR G ASST PROF
DEPT OF MEDICINE
MDS• Disorders of multipotent hemopoietic stem cell
• Heterogenous group
• Hemopoiesis is ineffective and morphological dysplastic ( Blood/ BM)
• Tendency to evolve into acute leukemia
• Elderly patient
Definition:• A group of clonal bone marrow stem cell
disorders, characterized by hypercellular marrows, peripheral cytopenias, and cell functional abnormalities–Ineffective hematopoiesis
• Highly variable natural history• High mortality rate
• Unless permanent control achieved (by alloBMT) death due to bone marrow failure, with or without conversion to AML
FAB (1982)• Refractory anemia (RA)• Refractory anemia with ring sideroblast (RARS)• Refractory anemia with excess blast (RAEB)• Refractory anemia with excess blast in• transformation (RAEBt)• Chronic myelomonocytic leukemia (CMML)
MDS: Limitations of FAB Classification
•Multilineage cytopenia with <5% BM blasts
•Rough prediction of prognosis
•Cytogenetics not given importance
• Immunophenotyping and genetic techniques not included
Comparison of MDS ClassificationsFAB classification
1982WHO Classification 2008
RA Refractory cytopenia with unilineage dyplasia• Refractory anemia• Refractory neutropenia• Refractory thrombocytopenia
RARS Refractory anemia with ring sideroblasts (RARS)
RCMD(Refractory cytopenia with multilineage dysplasia)
RCMD-RS
RAEB RAEB I and 2(excess blast)
RAEB-T RAEB II/ AML
CMML MDS-UC
MDS associated with isolated del(5q)
Childhood myelodysplastic syndrome• Refractory cytopenia of childhood
Predisposition: Acquired:Mutagen/Genotoxic Stress Therapeutic alkylators, Topo-II agents, -emitters (32P), autoSCT Environmental/occupational
(benzene) Tobacco
Aplastic anemiaPNH
List AF, et al. The Myelodysplastic Syndromes. In: Wintrobe’s Hematology 2003.
Heritable:Constitutional genetic disorders Trisomy 8 mosaicism Familial monosomy 7
Neurofibromatosis 1Embryonal dysgenesis (del12p)Congenital Neutropenia Kostmann, Schwachman-Diamond
DNA repair deficiencies Fanconi anemia, AT, Bloom syndrome
Pharmacogenomic polymorphisms (GSTq1-null)
Clinical Overlap / Associations:• AML • Aplastic anemia• Myeloproliferative disease• leukemia• Autoimmune diseases
AML
PRCA
PNH MDS
AA
LGL MPD
With Permission of J Maciejewski,M.D. Taussig Cancer Center/ Cleveland Clinic FoundationWith Permission of American College of Physicians from Young NS. Ann Intern Med. 2002 Apr 2;136(7):534-46 (ACP not responsible for accuracy of figure translation).
Diagnosis and Classification
Basic Diagnostic Evaluation:
• Peripheral blood counts + reticulocyte count
• Bone marrow biopsy and aspiration – Cytogenetics
• Auxiliary tests – FISH– Flow cytometry in indeterminate cases – Iron saturation, ferritin – B12, folate levels – EPO level
Establish diagnosis Assess – FAB/WHO classification – IPSS score (if applicable)
http:// www.NCCN.org MDS Guidelineshttp://www.hmds.org.uk/mds.html
Epling-Burnett and List. Curr Opin Hematol 2009;16:70
Advances in ManagementImproved prognostic scores
Disease related variablesHost factors
Appropriate clinical decisionDisease eradication/ controlProlonging overall survivalManaging complications of disease and therapyImproving quality of life
2012 Revised IPSS
Schanz J, et al. J Clin Oncol. 2012;30:820-829. Greenberg PL, et al. Blood. 2012;120:2454-2465.
Prognostic Subgroup
Cytogenetic Abnormality
Very good del(11q), -Y
Good Normal, del(20q), del(5q) alone or double, del(12p)
Intermediate +8, del(7q), i(17q), +19, any other single or double, independent clones
Poor inv(3)/t(3q)/del(eq), -7, double including del(7q), complex (3)
Very poor complex (≥ 3)
Fine tune the prognostic impact of •Cytogenetic abnormalities•Depth of cytopenia
IPSS-R
Risk Category Risk Score
Very low ≤ 1.5
Low >1.5 - 3
Intermediate >3 – 4.5
High >4.5 - 6
Very High >6
Variable 0 0.5 1 1.5 2 3 4Cytogenetics V. good - Good - Int Poor V. poorBM blast% ≤2 - >2 - <5 - 5-10 >10 -Hgb ≥10 - 8-<10 <8 - - -Platelets ≥100 50-100 <50 - - - -ANC ≥0.8 <0.8 - - - - -
Tools to treat MDS
• Observation• Supportive therapy (Transfusions)• Hematopoietic growth factors• Iron chelation• Lenalidomide (Revlimid 2005)• Hypomethylating agents
▫ Azacitidine (Vidaza 2004)▫ Decitabine (Dacogen 2006)
• Immunosuppression• Allogeneic stem cell transplantation• Newer agents
Role of Growth Factors
GCSF Support improves ANC (75% patients)Has no impact on overall survival.Not recommended for routine infection prophylaxis
Thrombopoietic agents
Most have no significant impact on transfusion needs:Main utility
– Fewer dose modifications of disease modifying agents– Romiplostim: weekly– Eltrombopag: under study
Erythropoiesis stimulating agents (ESA)
– First line therapy for IPSS low or Int-1 risk MDS with EPO <500U/L (NCCN guidelines)
– Response rates; 20-30%, – Epoeitin alpha: 60,000-80,000 U once per week– Darbopoietin alpha: 500mcg once 3 weekly
Most widely prescribed class of medications for MDS (55%)
Biological response modifiersspecial case of Del 5q syndrome
Eligibility: •del(5q)•IPSS low or Int-1•platelets > 50K/mm3
•neutrophils > 500/mm3
• transfusion dependent
Hypomethylating agents
Hypomethylating agents
•
• Azacytidine and decitabine are potent DNMT inhibitors
• This leads to hypomethylation of dinucleotides in gene promoters and reactivation of previously silent genes
Hypomethylating agentsWhen to start
– Int/ high risk MDS (IPSS)– Transfusion dependent/ EPO failure– Not yet known if early treatment is better than late treatment in MDS
Which drug– NCCN recommends Azacitidine preference over Decitabine– EORTC study failed to show survival benefit.– MDACC regimen (5 day 20mg/m2/d) highest CR
Duration– Optimal duration- not known– To treat responding pts till disease progression, as long as tolerated– At least 4 cycles recommended for adequate response
Steensma et al. Hematol Oncol clin N Am 2010
MDSLow risk
(low or Int 1, BM blasts <10%)
Any age
Iron ChelationGrowth factorsDMT InhibitorsLenolidamide
Progression/ failure
HSCT
High Risk(Int 2, High risk, blasts>10%)
Age <60 Age≥60
Intensive chemoDMTI
DMTIIntensive Chemo
FailureFailure
MYELOPROLIFERATIVE DISORDERS
The myeloproliferative diseases (MPDs) are clonal stem cell disorders characterised by leukocytosis, thrombocytosis, erythrocytosis, splenomegaly, and bone marrow hypercelularity
Myeloproliferative Disorders(old classification)
a group of disease characterized by overgrowth of one or more hematologic cell lines in BM
1. chronic myelogenous leukemia (CML)2. polycythemia vera (PV)3. essential thrombocythemia4. agnogenic myeloid metaplasia/myelofibrosis
www.freelivedoctor.com
Myeloproliferative Disorders(2008 WHO classification)
1. polycythemia vera2. chronic idiopathic myelofibrosis3. essential thrombocytosis4. chronic myeloid leukemia (CML)5. [chronic neutrophilic leukemia]6. [chronic eosinophilic leukemia]7. [hypereosinophilic syndrome]8.Mast cell disease
“myelodysplastic/myeloproliferative diseases”juvenile myelomonocytic leukemiaatypical chronic myeloid leukemia (lacking t(9;22))chronic myelomocytic leukemia
www.freelivedoctor.com
Polycythemia Vera(lots of red cells - for real)
An uncommon disorder - distinguish from other causes of erythrocytosisDiagnosis depends on knowledge of erythropoeisisComplications most commonly from thrombosis and vascular incidentsLong natural history with treatment
Definition of Erythrocytosis
Normal hematocrit : Male 47 5 percent Female 42 5 percent
Normal hemoglobin : Male 15 2 gm/dl Female 13.5 1.5 gm/dl
Absolute vs. Relative Erythrocytosis
Normal Spurious Polycythemia
Plasma VolRBC
Pathophysiology of Polycythemia
Secondary Polycythemia
Inappropriate EPO (ectopic production) Tumors (hepatoma, renal carcinoma,
leiomyoma, hamartoma) Renal disorders (transplantation, cysts) hemangiomas Androgen abuse EPO abuse Familial polycythemia
Polycythemia VeraP. vera is a rare diseaseMedian age 60 - 65 yearsClinical features Attributed to increased blood viscosity and
poor oxygen delivery to organs (brain) Poor O2 delivery leads to ischemia and
thrombosis Expanded blood volume and viscosity
leads to increased cardiac work load
P. Vera - Symptoms & Signs
Symptoms Headache Weakness Pruritis
(aquagenic) Dizziness Diaphoresis Visual
disturbance Weight loss
Signs Splenomegaly
70% Skin plethora
67% Hepatomegaly
40% Conjunctival
plethora 59% Systolic
Hypertension 72%
P. Vera - Diagnosis (PVSG criteria)
Criteria RBC mass
elevated SaO2 > 92% Splenomegaly
(or)thrombocytosisLeukocytosishigh LAPhigh B12
Significance True vs. spurious R/O most 2
causes Evidence for MPD
False Positive 0.5% smokers, drinkers
Diagnosis of Polycythemia Vera
Major Criteria1. Hgb level > 18.5 g/dL in men, >16.5 g/dL in women2. Presence of the JAK2V617F mutation (in 95% of patients)
Minor Criteria3. Bone marrow biopsy showing hypercellularity4. Serum Epo level below normal range5. Endogenous erythroid colony formation in vitro
PV is likely if:A. Both major criteria and at least 1 minor criterion are met, orB. First major criterion and at least 2 minor criteria are met
Treatment of Polycythemia Vera (PV)
Control and maintain Hct levels <45%
Manage disease-related complications of PV
Phlebotomy to maintain Hct levels <45%
Low-dose aspirin in appropriate patients
Hydroxyurea or IFNα as first-line cytoreductive therapy at any age
Patients with inadequate response to or intolerance of HU use Ruxolitinib (Jakifi) JAK2 inhibitor
Anagrelide (0.5 mg qds/d) is used mainly to manage thrombocytosis in patients refractory to other treatments.
Essential Thrombocythemia
Essential Thrombocythemia
Rare disorder (1.5 per 100,000)proliferation of megakaryocytes causing marked increase in circulating platelets (>1 million)morphologically abnormal plateletssplenomegaly, mucosal hemorrhage, thromboses
arrow: macrothrombocyte
www.freelivedoctor.com
Essential Thrombocythemia
Incidence: 1.5 per 100,000Age at Dx: 60 y/o (~20% <40 y/o)F to M ratio: 1.6 : 1Social risk factor: 1. long-term use of dark hair dyes
2. living in tuff house3. electrician
Clinical features: - near normal life expectancy- frequent vasomotor and thrombo- hemorrhagic episodes
Treatment: low-dose acetylsalicylic acid
www.freelivedoctor.com
MyelofibrosisBone marrow fibrosis
• fibroblasts may be “innocent bystanders”• fibrosis probably driven by neoplastic megakaryocytes
Middle aged adults (50-60 y/o)
extramedullary hematopoiesis (spleen, liver)
May occur as an extension of CML or PV
Abnormal peripheral RBCs (“tear-drop” & nucleated RBCs)
Immature WBC and abnormal platelets
Infection, thrombosis and hemorrhage as a major complicationwww.freelivedoctor.com
Myelofibrosis
LARGE AND BIZARRE PLATELETS, LEUKOCYTOSIS
“naked” nuclear fragments
www.freelivedoctor.com
TREATMENT
1.SPLENECTOMY
2. CORRECT VITAMIN DEF
3. ALLOGENIC BONE MARROW TRANSPLANT
CHRONIC MYELOID LEUKEMIA
Definition• Chronic myelogenous leukemia is a pluripotent
stem cell disease characterized by anaemia,extreme blood granulocytosis with immaturity ,basophilia,thrombocytosis and splenomegaly.
• Occurs more often in men.
• Disease of firsts.
• High doses of ionising radiation can increase the occurrence of CML.
Pathophysiology• Genetic hallmark of CML is the presence of
BCR-ABLfusion gene product.• The fusion protein is a result of reciprocal
translocation between the abelson oncogene on chromosome 9 and break point cluster region on chromosome 22.
• Fusion genes are generated that encode 190,210,or 230 kda forms of the BCR-ABL tyrosine kinase.
Other genetic abnormalities• Trisomy 8,p53 loss.• Interleukin 1 b involved in the progression of
CML to the blastic phase.
CML Pathogenesis: Philadelphia (Ph) Chromosome
47
CML first cancer demonstrated to have underlying genetic abnormality
• Associated with Ph chromosome Result of translocation between chromosomes 9
and 22 Detected in approx. 95% of patients with CML
Clinical presentation Symptoms• Fatigue,malaise• Weight loss• Early satiety • Left upper quadrant pain or mass• Easy bruising ,bleeding• FeverUncommon presentation• Acute gouty arthritis,priapism,myocardial
infarction,venous thrombosis,visual disturbances,sweet syndrome..
Signs• pallor• Splenomegaly• Sternal tenderness• Lymhadenopathy• Hepatomegaly• Purpura• Retinal haemorrhage
Diagnostic approach to CMLPeripheral blood• Granulocytic leukocytosis>50*10p9/l• Predominance of neutrophils and increased %of
myelocytes.• Absolute basophilia.• Platelets are normal or increased in number.Bone marrow• Marrow is hypercellular with granulocytic
predominance.• Megakaryocytes are increased in number with
abnormal morphology.• Increase in reticulin fibrosis.• Blasts less than 5%.
Band forms
promyelocyte
myelocyte
metamyelocyte
Diagnosis of accelarated phase• Blasts 10-20% in peripheral blood and or
bone marrow.• Basophils >20% in peripheral blood.• Persistent thrombocytopenia.• Increasing spleen size and white blood
count despite therapy.• Cytogenetic evidence of clonal evolution.
ACCELERATED PHASE
MYELOBLAST
Blast crisis phase• Blast > 20%• Extramedullary blast proliferation.• Large aggregates or clusters of blast in
bone marrow.
Clinical Presentation of Ph+ CML
56
Other abnormalities There is increase in • uric acid level• vitamin B12 level.• lactate dehydrogenase.• Increase in the level of angiogenic factors.• Decrease level of leukocyte alkaline
phosphatase.• Increase in histamine levels.
• Identification of philadelphia chromosome• Can be done by conventional cytogenetic
karyotyping,FISH,RT-PCR.Conventional cytogenetics• Entire chromosomal complement is
evaluated to identify philadelphia chromosome and other abnormalities.
• Can be done on both peripheral blood and bone marrow.
Disadvantage• Presence of cryptic or submicroscopic
BCR-ABL arrangement cannot be identified
Fluorescent insitu hybridisationAdvantage• Fast results,greater sensitivity than
conventional cytogenetics.• cryptic molecular alteration can be
detected.Reverse transciptase-PCR• Detects different length products
corresponding to chimeric BCR-ABL proteins of 190,210 and 230 kda.
• So helps in distinguishing CML from ALL.
Fluorescent insitu hybridisation
Prognostic factorsSokal index• Percentage of circulating blast,spleen
size,platelet count,age and cytogenetic clonal evolution.
• Was developed based on chemotherapy treated patients.
Hassford system• Developed on interferon alpha treated patients.• Includes% of circulating blast,spleen
size,platelet count,age,% of eosinophils and basophils.
Treatment • Drugs • Stem cell transplant.• Leukaphresis and splenectomy.drugs• Imatinib mesylate,dasatinib,nilotinib• Hydroxyurea• busulphan• Interferon-alpha• Homoharringtonine• Anagrelide.• Cytarabin.
Imatinib• It is an ABL specific tyrosine kinase
inhibitor.• Imatinib induces apoptosis in cells
expressing BCR/ABL.• Dose is 400mg/day.• It should achieve cytogenetic remission
by 6months and molecular remission by 18 months.
• Side effects-edema,pleural and pericardial effusion,nausea,vomiting,diarrhoea,muscle cramps,skin rash,bone pain and arthralgia.myelosuppression.
Imatinib Mechanism of Action
64
Criteria for Extent of Imatinib Treatment
. Hematologic response -White cell count <10x109(platelet count <450 x 109/L, no immature myeloid cells in the blood, and disappearance of all signs and symptoms related to leukemia (including palpable splenomegaly) lasting for at least 4 weeks.
• Major cytogenetic response-Less than 35% of cells containing the Ph chromosome by cytogenetic analysis of marrow cells.
• Complete cytogenetic response-No cells containing the Ph chromosome by cytogenetic analysis of marrow cells.
• Major molecular response-Blood cell BCR-ABL ratio <0.05% (3-log reduction in PCR signal from mean pretreatment baseline value)
• .Complete molecular response-Blood cell BCR-ABL levels undetectable (usually by nested RT-PCR method).
Guidelines for response to imatinib treatment
Time of observation
unsatisfactory
Suboptimal response
Optimal response
3 MONTHS NoHR pHR CHR
6 No mcyR mcyR McyR
12 noMCYR McyR CcyR
18 noCcyR CcyR MMR
Newer tyrosine kinase inhibitorsDasatinib• Structurally unrelated to imatinib binds to
the ABL kinase domain.• Side effect-myelosuppression,pleural
effusion,prolongation of QT interval.Nilotinib• Structural derivative of imatinib binds to
ABL kinase domain.• Side effects-rashes,transient elevation of
indirect bilirubin levels and myelosuppression.
Hydroxy urea• Inhibitor of ribonucleotide reductase.• Lower the blood counts in 1-2 days.• Dose is 500-3000 mg/day.• Side effect-nausea and skin rash.• Given for patients intolerant to imatinib.Busulphan• Gradually lowers the blood counts.• Dose-6-10 mg/day.• Should not be used in patients expected to
undergo bonemarrow transplantation.
Interferon alpha• Causes complete haemotologic response
in >70% of patients.• Dose is 5 million units daily by
subcutaneous administration.• Hasford score was developed to predict
the survival of patients treated with interferon alpha.
Homoharringtonine• it is a plant alkaloid causes cytogenetic
response in patients in late chronic phase.
Anagrelide• It is used for treating elevated platelet
count in CML.especially in presence of thrombosis and bleeding
Leukapheresis• Control CMLonly temporarily.• Used in hyperleucocytic patients where
rapid cytoreduction can reverse the symptoms.
• Pregnant patient with CML can be controlled by leukaphresis.
Allogenic stem cell transplant• Outcome depends on patients age,phaseof
disease,type of donor,preparative regimen,graft vs host disease,post transplantation treatment.
• Patients age should be less than 70 years.transplantation from donor should be HLA matched.
• Peripheral blood can be used a source of haemotopoietic progenitor cells.preoperative regimen like cyclophosphamideplus total body irradiationis used.
• Complications-graft vs host disease.
Differential diagnosis• Chronic myelomonocytic leukemia• Juvenile myelomonocytic leukemia• Chronic neutophilic leukemia• Atypical CML• Diseases associated with
hypereosinophilia.
Chronic myelomonocytic leukemia• Anemia, monocytosis >1000/l; blood blasts <10%;
increased plasma and urine lysozyme; BCR rearrangement absent; uncommon cases with PDGFR- mutation respond to imatinib.
• Chronic eosinophilic leukemia• Blood eosinophil count >1500/l; cardiac and neurologic
manifestations common; a proportion of cases have PDGFR- mutations and are responsive to imatinib mesylate.
Chronic monocytic leukemia• Proportion of monocytes elevated; very rare form of
leukemia.Juvenile myelomonocytic leukemia• Infants and children <4 years; eczematoid or
maculopapular rash; anemia and thrombocytopenia; increased HgF in 70% of cases; neurofibromatosis in 10% of cases; BCR rearrangement absent .
THANK YOU
Most CML Patients Are Diagnosed in the Chronic Phase
80
Chronic Phase 80% Blast Phase 10%
CML Pathogenesis: Philadelphia (Ph) Chromosome
81
CML first cancer demonstrated to have underlying genetic abnormality
• Associated with Ph chromosome Result of translocation between chromosomes 9 and 22 Detected in approx. 95% of patients with CML
Clinical Presentation of Ph+ CML
83
Treatment of CML • Imatinib (Gleevec), developed by Dr. Brian Druker at Oregon
Health & Sciences University and Novartis pharmaceutical company in mid-1990.
• Also found to be effective in other blood cancers and GIST by inhibiting different TK proteins.
• World-wide sales now $28 billion in the 10 years from 2001-2011.
• Now 4 drugs, second generation tyrosine kinase inhibitors available to treat CML.
• Drugs continue throughout life.
84
Imatinib Mechanism of Action
85
Treatment of CML• 4 Targeted drugs which block the action of tyrosine kinase
(TKIs): – Imatinib (Gleevec)– Dastinib (Sprycel)– Nilotinib (Tasigna)– Bosutinib (Bosulif)
• Side Effects– Skin rash– Fluid retention– Diarrhea– Vascular thrombosis
• Omacetaxine (Synribo) or Homoharringtonine (alkaloid) approved use when 2 TKIs have failed
86
Event-Free Survival and Survival Without AP/BC on First-Line Imatinib
87
Survival Rates for Stem Cell Transplantation
88
‘Inverted Iceberg’ Schematic of CML burden and reduction over time.
89
CML Treatment Cessation of TKIs• If relapse occurs, it develops within the first 6 months after
the treatment stopped• About 40%—50% of patients have no recurrence if their
initial leukemic burden was low and they had been on treatment for a long duration (> 10 years)
• Ongoing studies investigating second generation TKIs e.g. nilotinib and achieving more rapid MMR > 4 – 5 logs
• Current recommendation is to continue with TKI treatment for life
• Patients may not be able to tolerate TKI and alternative drug chosen
90
THANK YOU
Top Related